|
|
Volumn 112, Issue , 2002, Pages 305-322
|
|
Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALKYLATING AGENT;
ANTINEOPLASTIC AGENT;
DNA;
DNA DIRECTED DNA POLYMERASE;
DNA TOPOISOMERASE;
GLUTATHIONE;
GLUTATHIONE TRANSFERASE;
MELPHALAN;
ALKYLATION;
APOPTOSIS;
DNA REPAIR;
DRUG RESISTANCE;
HUMAN;
METABOLISM;
NEOPLASM;
REVIEW;
ALKYLATION;
ANTINEOPLASTIC AGENTS, ALKYLATING;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
APOPTOSIS;
DNA;
DNA REPAIR;
DNA TOPOISOMERASES, TYPE I;
DNA-DIRECTED DNA POLYMERASE;
DRUG RESISTANCE, NEOPLASM;
GLUTATHIONE;
GLUTATHIONE TRANSFERASE;
HUMANS;
MELPHALAN;
NEOPLASMS;
MLCS;
MLOWN;
|
|
EID: 1842865943
PISSN: 09273042
EISSN: None
Source Type: Journal
DOI: 10.1007/978-1-4615-1173-1_15 Document Type: Review |
|
Times cited : (18)
|
|
References (91)
|
